Quintiles is partnering with British genomics testing company Population Genetics Technologies in a move that broadens the clinical research organization’s capability to bring genetic testing and analysis into the clinical development of drugs.
Durham, North Carolina-based Quintiles said it will work with PGT to find opportunities for large-scale genomic analysis, tests that use samples from as many as thousands of individuals, to test and find the connection of biomarkers to drug response. This kind of large-scale testing has been expensive, but Quintiles says that PGT can make the process easier and less costly. PGT’s technology can process hundreds of genomes simultaneously, which accelerates large-scale population studies.
At ViVE 2024, Panelists Share Prior Authorization Progress and Frustration in Payer Insights Program
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
Financial terms of the partnership between the two privately held companies were not disclosed. The arrangement is nonexclusive and both companies say they will seek opportunities with other companies.
Senior vice president of Quintiles Innovation, M. King Jolly, said in a prepared statement that the companies believe the partnership will increase the probability of success in clinical trials, reduce trial enrollment required to reach statistical significance and reduce both the costs and the time required to bring new drugs to market.
“PGT’s technology combined with Quintiles’ global presence can bring the benefits of large-scale sequencing and analysis to virtually all biopharmaceutical companies,” Jolly said.
PGT Chief Commercial Officer Frank Massam said that the companies’ first project is a renal cancer clinical trial to identify genetic markers that are predictive of both adverse events and efficacy. The company has also applied its technology to programs in breast cancer, leukemia and Alzheimer’s disease.
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Quintiles is the CRO industry’s largest provider with more than $3 billion in annual revenue. The company has operations in 60 countries.
